Back to company

XGX Pharma ApS: Financial statements 2018

CVR: 32289290

XGX Pharma ApS (CVR 32289290) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 1,574,797 and a net result of DKK 26,878 compared with DKK -189,057 the year before. That is an increase of 1,408% compared with the year before. Equity amounted to DKK 59,347. The solvency ratio was 1.7%. The company had 1 employee in the financial year.

Gross Profit
1,574,797 kr.
Profit/Loss
26,878 kr.
Equity
59,347 kr.
Total Assets
3,486,915 kr.
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2018-1.6 mio.27 t.59 t.1
2017-104 t.-189 t.32 t.-
2016-307 t.272 t.92 t.-
2015--33 t.-35 t.-180 t.-
2014---14 t.-145 t.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on XGX Pharma ApS

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2018

Mohammad Sohail Asghar joins the board of XGX Pharma ApSNov 1, 2018

As of November 1, 2018, Mohammad Sohail Asghar has joined the board of directors of XGX Pharma ApS.

Per Ludvigsen joins the board of XGX Pharma ApSNov 1, 2018

As of November 1, 2018, Per Ludvigsen has joined the board of directors of XGX Pharma ApS.

Jens-Nikolaj Schøier joins the board of XGX Pharma ApSNov 1, 2018

As of November 1, 2018, Jens-Nikolaj Schøier has joined the board of directors of XGX Pharma ApS.

XGX Pharma ApS: The 2017 annual report is outJun 19, 2018

XGX Pharma ApS has published its annual report for 2017. Gross profit came to DKK 104,432, and the net result was DKK -189,057.

About XGX Pharma ApS

XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Jens-Nikolaj Schøier. The company is owned by Unimedic Pharma AB. The company has 2 employees. In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity amounted to DKK 30,787,180.